TrialEuropean journal of pain (London, England)2017

Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.

D Dupoiron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.